Celgene Corp (CELG) 115.92 $CELG
Jim Cramer's 'Mad Money' Recap: Nowhere to Run, Nowhere to Hide
at The Street - Wed Oct 21, 6:50PM CDT
Some days you get mauled in the market, other days you might not, says Cramer.
GE: 28.85 (+0.07), CLX: 122.06 (-0.02), HON: 98.77 (+0.49), UTX: 97.97 (+2.35), KSU: 87.41 (-1.25), KMB: 118.09 (+0.87), SLB: 75.63 (+0.08), SAP: 76.17 (+0.71), LGF: 39.18 (-0.66), CHK: 7.87 (-0.32), S: 4.34 (-0.02), CMG: 665.67 (-39.96), AMAG: 36.37 (+1.30), TMUS: 40.22 (-0.48), TWTR: 29.30 (-1.61), UNP: 93.41 (-0.33), MU: 16.43 (-0.66), TSN: 46.23 (+0.14), WDC: 71.44 (-3.42), BA: 141.19 (+2.31), TUP: 59.81 (+4.61), CELG: 115.92 (-0.32), CRC: 3.99 (-0.21), TXN: 51.90 (-0.53), GM: 35.42 (+1.94), RACE: 55.00 (-5.00), VZ: 44.86 (-0.38), SNDK: 76.78 (+1.59)
Battle Royale: Gilead Sciences Inc vs Celgene Corporation
Brian Feroldi, The Motley Fool - Motley Fool - Wed Oct 21, 2:09PM CDT
Photo by Mattza / Flickr creative Commons It's been a rough couple of months to be a biotech focused investor. Since peaking in price over the summer, biotech stocks on the whole have basically been in free-fall. The iShares Nasdaq Biotechnology...
GILD: 101.73 (+0.07), CELG: 115.92 (-0.32)
Stocks Turn Lower as Valeant Dents Biotech Sector
at The Street - Wed Oct 21, 9:41AM CDT
Stocks turn lower by mid-morning Wednesday as plummeting Valeant Pharmaceuticals shares pull the biotech sector to the downside.
BIIB: 276.34 (+10.53), TSLA: 210.09 (-2.94), VRX: 118.61 (-28.13), KMB: 118.09 (+0.87), IBB: 304.46 (-1.50), SBUX: 60.53 (-0.35), YHOO: 31.12 (-1.71), CMG: 665.67 (-39.96), ABBV: 53.83 (-1.00), GOOGL: 671.80 (-8.20), AAPL: 113.76 (-0.01), KO: 42.19 (-0.10), AMZN: 555.77 (-5.11), MU: 16.43 (-0.66), PFE: 33.46 (-0.54), FCAU: 15.20 (-0.74), BA: 141.19 (+2.31), WDC: 71.44 (-3.42), CELG: 115.92 (-0.32), GILD: 101.73 (+0.07), LRCX: 70.79 (+0.76), GM: 35.42 (+1.94), MCD: 102.54 (-1.30), KLAC: 63.98 (+10.12), RACE: 55.00 (-5.00), SNDK: 76.78 (+1.59)
Stock Market News for October 21, 2015
Zacks Equity Research - Zacks Investment Research - Wed Oct 21, 9:10AM CDT
Benchmarks ended in the red on Tuesday, dragged down by declines in biotech and healthcare stocks
BIIB: 276.34 (+10.53), HOG: 47.03 (-1.22), IBM: 140.92 (+0.28), GILD: 101.73 (+0.07), UTX: 97.97 (+2.35), PFE: 33.46 (-0.54), MRK: 50.59 (+0.20), AMGN: 150.09 (-0.36), VZ: 44.86 (-0.38), REGN: 518.53 (+3.86), TRV: 110.70 (+1.75), CELG: 115.92 (-0.32)
Rotation Is Enough to Make Your Head Spin
at The Street - Tue Oct 20, 1:17PM CDT
Bad news isn't always a bad thing.
AMZN: 555.77 (-5.11), TSLA: 210.09 (-2.94), VRX: 118.61 (-28.13), HOG: 47.03 (-1.22), LMT: 211.56 (+2.83), ETN: 52.52 (+0.15), CLX: 122.06 (-0.02), UTX: 97.97 (+2.35), DAL: 49.44 (-0.71), CELG: 115.92 (-0.32), AGN: 259.00 (-4.42), GILD: 101.73 (+0.07), IBM: 140.92 (+0.28), GOOGL: 671.80 (-8.20), DOV: 61.88 (+0.35), PG: 73.59 (-0.84), PPG: 100.64 (-0.74), REGN: 518.53 (+3.86)
Look for Shares of Celgene to Potentially Pullback after Yesterday's 1.30% Rise
Comtex SmarTrend(R) - Mon Oct 19, 3:53PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $116.66 to a high of $120.27. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $118.64 on volume of 4.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 115.92 (-0.32)
SmarTrend Watching for Potential Pullback in Shares of Celgene After 1.30% Gain
Comtex SmarTrend(R) - Mon Oct 19, 3:53PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $116.66 to a high of $120.27. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $118.64 on volume of 4.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 115.92 (-0.32)
Stocks Deserve a Second Look as Rally Remains Intact
at The Street - Mon Oct 19, 1:42PM CDT
The CNBC 'Fast Money' traders are becoming more content with the legitimacy of the current rally. Apple and Nike are also discussed.
AMZN: 555.77 (-5.11), NKE: 132.47 (+0.10), FB: 97.11 (+0.11), GOOG: 642.61 (-7.67), MS: 31.48 (-0.77), CELG: 115.92 (-0.32), LEN: 52.09 (+0.27), BBBY: 57.72 (-0.74), SPY: 201.85 (-1.24), EBAY: 24.21 (-0.21), GOOGL: 671.80 (-8.20), XLF: 23.50 (-0.17), AAPL: 113.76 (-0.01)
Phase 2 Maintenance Data from Oral Ozanimod TOUCHSTONE Study in Ulcerative Colitis Presented at ACG Plenary Session
Business Wire - Mon Oct 19, 7:00AM CDT
--Clinical response and mucosal healing also significantly improved with Ozanimod 1 mg compared to placebo at week 32
CELG: 115.92 (-0.32)
Celgene names Julia A. Haller, MD to board
M2 - Mon Oct 19, 3:06AM CDT
Biopharmaceutical company Celgene Corporation (NasdaqGS:CELG) revealed on Friday the addition of Julia A. Haller, MD to its board of directors.
CELG: 115.92 (-0.32), CELGZ: 1.65 (+0.01)
PEP, KMB, STX, IBM: Jim Cramer's Views
at The Street - Mon Oct 19, 12:00AM CDT
Jim Cramer shares his views on the chicken growth stocks and intra-sector rotations. Pepsico, Kimberly-Clark, Seagate Technology and IBM are among the stocks discussed here.
MU: 16.43 (-0.66), AMZN: 555.77 (-5.11), GE: 28.85 (+0.07), SWKS: 77.67 (-0.62), CLX: 122.06 (-0.02), STX: 37.13 (-1.39), KMB: 118.09 (+0.87), WMT: 58.64 (-0.11), LLY: 77.01 (-0.78), NXPI: 91.32 (-0.67), WDC: 71.44 (-3.42), INTC: 33.37 (-0.07), HPQ: 28.23 (-0.33), PEP: 100.25 (-0.02), CELG: 115.92 (-0.32), QRVO: 48.50 (+0.30), IBM: 140.92 (+0.28), KHC: 77.05 (+0.18), SNDK: 76.78 (+1.59), REGN: 518.53 (+3.86), AVGO: 120.50 (+0.61), CRM: 75.83 (-1.70)
3 Biotechs Growing Faster Than Apple
Brian Feroldi, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Sun Oct 18, 12:02PM CDT
Image source: picaidol via Pixabay. If I (Brian Feroldi here!) could rewind the clock a decade or so and invest in one growth stock, it would probably be Apple , as the iPhone maker's growth over the past 10 years has simply been astounding. The...
ALXN: 160.31 (+1.29), AAPL: 113.76 (-0.01), REGN: 518.53 (+3.86), CELG: 115.92 (-0.32)
3 Blue-Chip Biotech Stocks Worth Buying for the Long Haul
Brian Feroldi, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Sat Oct 17, 11:25AM CDT
Image source: NWABR Flickr Creative Commons. While the stock market in general has been sold off over the last few months, healthcare-related stocks have fallen much harder than the rest of the market. The Vanguard Health Care ETF , for example,...
BIIB: 276.34 (+10.53), AMGN: 150.09 (-0.36), VHT: 125.55 (-1.26), CELG: 115.92 (-0.32)
Investing Moves for a No-Growth World; ETF Distortion: Jim Cramer's Best Blogs
at The Street - Fri Oct 16, 8:00PM CDT
Catch up on Jim Cramer's ideas from this past week as he discusses the shift to higher-risk investing, and the outsize power of ETFs and futures in the market now.
BIIB: 276.34 (+10.53), BMRN: 103.94 (+0.02), DAL: 49.44 (-0.71), C: 51.81 (-1.03), WMT: 58.64 (-0.11), KKR: 17.05 (+0.08), PANW: 159.81 (-6.25), ADBE: 86.13 (-0.71), V: 75.46 (-0.82), DG: 67.55 (+0.52), GOOGL: 671.80 (-8.20), CAT: 69.67 (-0.60), MA: 96.60 (-1.07), REGN: 518.53 (+3.86), AMZN: 555.77 (-5.11), KR: 38.08 (+0.36), SWKS: 77.67 (-0.62), FB: 97.11 (+0.11), NXPI: 91.32 (-0.67), BA: 141.19 (+2.31), CELG: 115.92 (-0.32), NFLX: 97.96 (-1.03), HCA: 71.20 (-1.22), AA: 9.11 (-0.30), GS: 179.70 (-5.81), QRVO: 48.50 (+0.30), GILD: 101.73 (+0.07), RHT: 76.81 (-1.45), WDAY: 78.23 (-1.65), FDC: 15.36 (-0.04), AVGO: 120.50 (+0.61), BABA: 69.48 (-2.31), CRM: 75.83 (-1.70)
Anatomy of a Rally: Simpler Than You Think
at The Street - Fri Oct 16, 1:00PM CDT
Understanding why stocks act the way they do.
AMZN: 555.77 (-5.11), GE: 28.85 (+0.07), CLX: 122.06 (-0.02), KMB: 118.09 (+0.87), KHC: 77.05 (+0.18), WMT: 58.64 (-0.11), LLY: 77.01 (-0.78), REGN: 518.53 (+3.86), CRM: 75.83 (-1.70), CELG: 115.92 (-0.32), PEP: 100.25 (-0.02)
Celgene Corporation Elects Julia A. Haller, M.D., to Its Board of Directors
Business Wire - Fri Oct 16, 7:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced the election of Julia A. Haller, M.D., to its Board of Directors. Dr. Haller is Ophthalmologist-in-Chief of the Wills Eye Hospital in Philadelphia, PA where she holds the William Tasman, M.D. Endowed Chair. She serves as Professor and Chair of the Department of Ophthalmology at Jefferson Medical College of Thomas Jefferson University and Thomas Jefferson University Hospitals, and is Co-Director of the Wills Vision Research Center at Jefferson.
CELG: 115.92 (-0.32), CELGZ: 1.65 (+0.01)
Jim Cramer's 'Mad Money' Recap: Buy Growth Where You Can
at The Street - Thu Oct 15, 7:12PM CDT
Investors are looking in even the most hated sectors, Cramer says.
BIIB: 276.34 (+10.53), GE: 28.85 (+0.07), BOX: 12.64 (-0.79), BX: 33.62 (+0.26), BMRN: 103.94 (+0.02), BBT: 36.28 (-0.47), FB: 97.11 (+0.11), ELNK: 8.23 (-0.20), WMT: 58.64 (-0.11), LPI: 11.69 (-0.87), CELG: 115.92 (-0.32), CG: 18.79 (-0.01), ETP: 45.53 (-1.41), GILD: 101.73 (+0.07), GOOGL: 671.80 (-8.20), OXY: 72.01 (-0.57), BABA: 69.48 (-2.31)
Pfizer's Oral Formulation of Xeljanz Gets CRL from the FDA
Zacks Equity Research - Zacks Investment Research - Thu Oct 15, 3:40PM CDT
Pfizer (PFE) announced that the FDA has served a CRL on its supplemental new drug application for oral Xeljanz for moderate-to-severe chronic plaque psoriasis.
NVO: 54.41 (-0.28), PFE: 33.46 (-0.54), NVS: 91.59 (-0.74), CELG: 115.92 (-0.32)
Jim Cramer's 'Mad Money' Recap: Nowhere to Run, Nowhere to Hide
at The Street - Wed Oct 21, 6:50PM CDT
Some days you get mauled in the market, other days you might not, says Cramer.
GE: 28.85 (+0.07), CLX: 122.06 (-0.02), HON: 98.77 (+0.49), UTX: 97.97 (+2.35), KSU: 87.41 (-1.25), KMB: 118.09 (+0.87), SLB: 75.63 (+0.08), SAP: 76.17 (+0.71), LGF: 39.18 (-0.66), CHK: 7.87 (-0.32), S: 4.34 (-0.02), CMG: 665.67 (-39.96), AMAG: 36.37 (+1.30), TMUS: 40.22 (-0.48), TWTR: 29.30 (-1.61), UNP: 93.41 (-0.33), MU: 16.43 (-0.66), TSN: 46.23 (+0.14), WDC: 71.44 (-3.42), BA: 141.19 (+2.31), TUP: 59.81 (+4.61), CELG: 115.92 (-0.32), CRC: 3.99 (-0.21), TXN: 51.90 (-0.53), GM: 35.42 (+1.94), RACE: 55.00 (-5.00), VZ: 44.86 (-0.38), SNDK: 76.78 (+1.59)
Battle Royale: Gilead Sciences Inc vs Celgene Corporation
Brian Feroldi, The Motley Fool - Motley Fool - Wed Oct 21, 2:09PM CDT
Photo by Mattza / Flickr creative Commons It's been a rough couple of months to be a biotech focused investor. Since peaking in price over the summer, biotech stocks on the whole have basically been in free-fall. The iShares Nasdaq Biotechnology...
GILD: 101.73 (+0.07), CELG: 115.92 (-0.32)
Stocks Turn Lower as Valeant Dents Biotech Sector
at The Street - Wed Oct 21, 9:41AM CDT
Stocks turn lower by mid-morning Wednesday as plummeting Valeant Pharmaceuticals shares pull the biotech sector to the downside.
BIIB: 276.34 (+10.53), TSLA: 210.09 (-2.94), VRX: 118.61 (-28.13), KMB: 118.09 (+0.87), IBB: 304.46 (-1.50), SBUX: 60.53 (-0.35), YHOO: 31.12 (-1.71), CMG: 665.67 (-39.96), ABBV: 53.83 (-1.00), GOOGL: 671.80 (-8.20), AAPL: 113.76 (-0.01), KO: 42.19 (-0.10), AMZN: 555.77 (-5.11), MU: 16.43 (-0.66), PFE: 33.46 (-0.54), FCAU: 15.20 (-0.74), BA: 141.19 (+2.31), WDC: 71.44 (-3.42), CELG: 115.92 (-0.32), GILD: 101.73 (+0.07), LRCX: 70.79 (+0.76), GM: 35.42 (+1.94), MCD: 102.54 (-1.30), KLAC: 63.98 (+10.12), RACE: 55.00 (-5.00), SNDK: 76.78 (+1.59)
Stock Market News for October 21, 2015
Zacks Equity Research - Zacks Investment Research - Wed Oct 21, 9:10AM CDT
Benchmarks ended in the red on Tuesday, dragged down by declines in biotech and healthcare stocks
BIIB: 276.34 (+10.53), HOG: 47.03 (-1.22), IBM: 140.92 (+0.28), GILD: 101.73 (+0.07), UTX: 97.97 (+2.35), PFE: 33.46 (-0.54), MRK: 50.59 (+0.20), AMGN: 150.09 (-0.36), VZ: 44.86 (-0.38), REGN: 518.53 (+3.86), TRV: 110.70 (+1.75), CELG: 115.92 (-0.32)
Rotation Is Enough to Make Your Head Spin
at The Street - Tue Oct 20, 1:17PM CDT
Bad news isn't always a bad thing.
AMZN: 555.77 (-5.11), TSLA: 210.09 (-2.94), VRX: 118.61 (-28.13), HOG: 47.03 (-1.22), LMT: 211.56 (+2.83), ETN: 52.52 (+0.15), CLX: 122.06 (-0.02), UTX: 97.97 (+2.35), DAL: 49.44 (-0.71), CELG: 115.92 (-0.32), AGN: 259.00 (-4.42), GILD: 101.73 (+0.07), IBM: 140.92 (+0.28), GOOGL: 671.80 (-8.20), DOV: 61.88 (+0.35), PG: 73.59 (-0.84), PPG: 100.64 (-0.74), REGN: 518.53 (+3.86)
Look for Shares of Celgene to Potentially Pullback after Yesterday's 1.30% Rise
Comtex SmarTrend(R) - Mon Oct 19, 3:53PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $116.66 to a high of $120.27. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $118.64 on volume of 4.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 115.92 (-0.32)
SmarTrend Watching for Potential Pullback in Shares of Celgene After 1.30% Gain
Comtex SmarTrend(R) - Mon Oct 19, 3:53PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $116.66 to a high of $120.27. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $118.64 on volume of 4.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 115.92 (-0.32)
Stocks Deserve a Second Look as Rally Remains Intact
at The Street - Mon Oct 19, 1:42PM CDT
The CNBC 'Fast Money' traders are becoming more content with the legitimacy of the current rally. Apple and Nike are also discussed.
AMZN: 555.77 (-5.11), NKE: 132.47 (+0.10), FB: 97.11 (+0.11), GOOG: 642.61 (-7.67), MS: 31.48 (-0.77), CELG: 115.92 (-0.32), LEN: 52.09 (+0.27), BBBY: 57.72 (-0.74), SPY: 201.85 (-1.24), EBAY: 24.21 (-0.21), GOOGL: 671.80 (-8.20), XLF: 23.50 (-0.17), AAPL: 113.76 (-0.01)
Phase 2 Maintenance Data from Oral Ozanimod TOUCHSTONE Study in Ulcerative Colitis Presented at ACG Plenary Session
Business Wire - Mon Oct 19, 7:00AM CDT
--Clinical response and mucosal healing also significantly improved with Ozanimod 1 mg compared to placebo at week 32
CELG: 115.92 (-0.32)
Celgene names Julia A. Haller, MD to board
M2 - Mon Oct 19, 3:06AM CDT
Biopharmaceutical company Celgene Corporation (NasdaqGS:CELG) revealed on Friday the addition of Julia A. Haller, MD to its board of directors.
CELG: 115.92 (-0.32), CELGZ: 1.65 (+0.01)
PEP, KMB, STX, IBM: Jim Cramer's Views
at The Street - Mon Oct 19, 12:00AM CDT
Jim Cramer shares his views on the chicken growth stocks and intra-sector rotations. Pepsico, Kimberly-Clark, Seagate Technology and IBM are among the stocks discussed here.
MU: 16.43 (-0.66), AMZN: 555.77 (-5.11), GE: 28.85 (+0.07), SWKS: 77.67 (-0.62), CLX: 122.06 (-0.02), STX: 37.13 (-1.39), KMB: 118.09 (+0.87), WMT: 58.64 (-0.11), LLY: 77.01 (-0.78), NXPI: 91.32 (-0.67), WDC: 71.44 (-3.42), INTC: 33.37 (-0.07), HPQ: 28.23 (-0.33), PEP: 100.25 (-0.02), CELG: 115.92 (-0.32), QRVO: 48.50 (+0.30), IBM: 140.92 (+0.28), KHC: 77.05 (+0.18), SNDK: 76.78 (+1.59), REGN: 518.53 (+3.86), AVGO: 120.50 (+0.61), CRM: 75.83 (-1.70)
3 Biotechs Growing Faster Than Apple
Brian Feroldi, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Sun Oct 18, 12:02PM CDT
Image source: picaidol via Pixabay. If I (Brian Feroldi here!) could rewind the clock a decade or so and invest in one growth stock, it would probably be Apple , as the iPhone maker's growth over the past 10 years has simply been astounding. The...
ALXN: 160.31 (+1.29), AAPL: 113.76 (-0.01), REGN: 518.53 (+3.86), CELG: 115.92 (-0.32)
3 Blue-Chip Biotech Stocks Worth Buying for the Long Haul
Brian Feroldi, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Sat Oct 17, 11:25AM CDT
Image source: NWABR Flickr Creative Commons. While the stock market in general has been sold off over the last few months, healthcare-related stocks have fallen much harder than the rest of the market. The Vanguard Health Care ETF , for example,...
BIIB: 276.34 (+10.53), AMGN: 150.09 (-0.36), VHT: 125.55 (-1.26), CELG: 115.92 (-0.32)
Investing Moves for a No-Growth World; ETF Distortion: Jim Cramer's Best Blogs
at The Street - Fri Oct 16, 8:00PM CDT
Catch up on Jim Cramer's ideas from this past week as he discusses the shift to higher-risk investing, and the outsize power of ETFs and futures in the market now.
BIIB: 276.34 (+10.53), BMRN: 103.94 (+0.02), DAL: 49.44 (-0.71), C: 51.81 (-1.03), WMT: 58.64 (-0.11), KKR: 17.05 (+0.08), PANW: 159.81 (-6.25), ADBE: 86.13 (-0.71), V: 75.46 (-0.82), DG: 67.55 (+0.52), GOOGL: 671.80 (-8.20), CAT: 69.67 (-0.60), MA: 96.60 (-1.07), REGN: 518.53 (+3.86), AMZN: 555.77 (-5.11), KR: 38.08 (+0.36), SWKS: 77.67 (-0.62), FB: 97.11 (+0.11), NXPI: 91.32 (-0.67), BA: 141.19 (+2.31), CELG: 115.92 (-0.32), NFLX: 97.96 (-1.03), HCA: 71.20 (-1.22), AA: 9.11 (-0.30), GS: 179.70 (-5.81), QRVO: 48.50 (+0.30), GILD: 101.73 (+0.07), RHT: 76.81 (-1.45), WDAY: 78.23 (-1.65), FDC: 15.36 (-0.04), AVGO: 120.50 (+0.61), BABA: 69.48 (-2.31), CRM: 75.83 (-1.70)
Anatomy of a Rally: Simpler Than You Think
at The Street - Fri Oct 16, 1:00PM CDT
Understanding why stocks act the way they do.
AMZN: 555.77 (-5.11), GE: 28.85 (+0.07), CLX: 122.06 (-0.02), KMB: 118.09 (+0.87), KHC: 77.05 (+0.18), WMT: 58.64 (-0.11), LLY: 77.01 (-0.78), REGN: 518.53 (+3.86), CRM: 75.83 (-1.70), CELG: 115.92 (-0.32), PEP: 100.25 (-0.02)
Celgene Corporation Elects Julia A. Haller, M.D., to Its Board of Directors
Business Wire - Fri Oct 16, 7:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced the election of Julia A. Haller, M.D., to its Board of Directors. Dr. Haller is Ophthalmologist-in-Chief of the Wills Eye Hospital in Philadelphia, PA where she holds the William Tasman, M.D. Endowed Chair. She serves as Professor and Chair of the Department of Ophthalmology at Jefferson Medical College of Thomas Jefferson University and Thomas Jefferson University Hospitals, and is Co-Director of the Wills Vision Research Center at Jefferson.
CELG: 115.92 (-0.32), CELGZ: 1.65 (+0.01)
Jim Cramer's 'Mad Money' Recap: Buy Growth Where You Can
at The Street - Thu Oct 15, 7:12PM CDT
Investors are looking in even the most hated sectors, Cramer says.
BIIB: 276.34 (+10.53), GE: 28.85 (+0.07), BOX: 12.64 (-0.79), BX: 33.62 (+0.26), BMRN: 103.94 (+0.02), BBT: 36.28 (-0.47), FB: 97.11 (+0.11), ELNK: 8.23 (-0.20), WMT: 58.64 (-0.11), LPI: 11.69 (-0.87), CELG: 115.92 (-0.32), CG: 18.79 (-0.01), ETP: 45.53 (-1.41), GILD: 101.73 (+0.07), GOOGL: 671.80 (-8.20), OXY: 72.01 (-0.57), BABA: 69.48 (-2.31)
Pfizer's Oral Formulation of Xeljanz Gets CRL from the FDA
Zacks Equity Research - Zacks Investment Research - Thu Oct 15, 3:40PM CDT
Pfizer (PFE) announced that the FDA has served a CRL on its supplemental new drug application for oral Xeljanz for moderate-to-severe chronic plaque psoriasis.
NVO: 54.41 (-0.28), PFE: 33.46 (-0.54), NVS: 91.59 (-0.74), CELG: 115.92 (-0.32)
